EXPERT CONSENSUS. ROLE OF COMBINATION LIPID-LOWERING THERAPY (SIMVASTATIN/EZETIMIBE 20/10 MG) IN THE CORRECTION OF LIPID METABOLISM DISTURBANCES IN PATIENTS WITH CHRONIC KIDNEY DISEASE

EXPERT CONSENSUS. ROLE OF COMBINATION LIPID-LOWERING THERAPY (SIMVASTATIN/EZETIMIBE 20/10 MG) IN THE CORRECTION OF LIPID METABOLISM DISTURBANCES IN PATIENTS WITH CHRONIC KIDNEY DISEASE

Expert Consensus. Role of combination lipid-lowering therapy (simvastatin/ezetimibe 20/10 mg) in the correction of lipid metabolism disturbances in patients with chronic kidney disease.

Saved in:
Bibliographic Details
Main Authors: A. Catapano, E. V. Shlyakhto, A. I. Martynov, R. G. Oganov, V. V. Kukharchuk, M. V. Shestakova, A. S. Ametov, S. A. Boicov, M. G. Bubnova, S. V. Villevalde, A. S. Galyavich, Yu. A. Karpov, J. D. Kobalava, O. N. Koziolova
Format: Article
Language:Russian
Published: «SILICEA-POLIGRAF» LLC 2013-08-01
Series:Кардиоваскулярная терапия и профилактика
Online Access:https://cardiovascular.elpub.ru/jour/article/view/217
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://cardiovascular.elpub.ru/jour/article/view/217

Similar Items